Early experience with percutaneous transcatheter implantation of heart valve prosthesis for the treatment of end-stage inoperable patients with calcific aortic stenosis.
By A. Cribier, H. Eltchaninoff, C. Tron, F. Bauer, C. Agatiello, L. Sebagh, Assaf Bash, D. Nusimovici, P. Litzler, J. Bessou and 1 more. Journal of the American College of Cardiology, 2004
701 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/5aa147210477254408dddf1c6f86d45d30650dcb
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Epidemiology
Citations in the corpus
- Percutaneous Transarterial Aortic Valve Replacement in Selected High-Risk Patients With Aortic Stenosis (2007, background): “Procedural success 43 (86) Stroke 2 (4) Myocardial infarction 1 (2) Ventricular fibrillation 2 (4) Heart block, new and sustained 2 (4) Tamponade* 1 (2) Transfusion 3 U 9 ( 18 ) Emergent cardiac surgery 0 (0) Endocarditis 0 (0) Death, intraprocedural 1 (2) Death, 30 d 6 (12) Death, stroke, or myocar”
- Treatment of calcific aortic stenosis with the percutaneous heart valve: mid-term follow-up from the initial feasibility studies: the French experience. (2006, methodology): “The materials and technique for implantation ave been previously described in detail (7,8,11).”
- Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium (2010, background): “Since the introduction of transcatheter aortic valve implantation (TAVI) in 2002(1), there has been increasing interest in the field of catheter-based treatment of high-surgical-risk patients with symptomatic aortic stenosis (AS).(2) – 7 Introduction of this new technology should ideally follow the ”